Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11850078 | 0.86 | CYP1A2 (0.48) | CYP1A2CHRM5ADRA2CACHESIGMAR1 | |
| SCHEMBL24146230 | 0.84 | CYP1A2 (0.44) | CYP1A2CHRM5ADRA2CACHESIGMAR1 | |
| SCHEMBL30340999 | 0.84 | CHRM5 (0.58) | CYP1A2CHRM5ADRA2CSIGMAR1CHRM3 | |
| SCHEMBL12945 | 0.84 | CHRM5 (0.58) | CYP1A2CHRM5ADRA2CSIGMAR1CHRM3 | |
| SCHEMBL3218288 | 0.84 | CHRM5 (0.58) | CYP1A2CHRM5ADRA2CSIGMAR1CHRM3 | |
| SCHEMBL10949210 | 0.81 | CHRM5 (0.54) | CYP1A2CHRM5ADRA2CSIGMAR1CHRM3 | |
| SCHEMBL18286778 | 0.81 | ALOX15 (0.48) | CYP1A2CHRM5ADRA2CACHESIGMAR1 | |
| SCHEMBL24008480 | 0.81 | KCNA3 (0.43) | CYP1A2CHRM5ADRA2CACHESIGMAR1 | |
| SCHEMBL17828184 | 0.81 | ACHE (0.64) | CYP1A2CHRM5ADRA2CACHESIGMAR1 | |
| SCHEMBL28750905 | 0.81 | CHRM5 (0.40) | CYP1A2CHRM5ADRA2CACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021262636-A2 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-12-30 | — | — | WO | disclosed |